Exogenus Therapeutics, a biotech company based in Portugal, has announced that it has contracted the contract development and manufacturing organization, Lonza, to develop a good manufacturing practice (GMP)-compliant process for Exogenus’ exosome-based lead candidate, Exo-101. Lonza will use its expertise in exosome development and analytical services at its Sienna, Italy site to define a process to produce Exo-101 for clinical supply. Source: Biopharm International 13/3/2025